Document:

Guaranty of Payment, dated May 30, 2008

 Exhibit 10.20 
 New York, New York 
 May 30, 2008 
 GUARANTY OF PAYMENT 
 FOR VALUE RECEIVED, and to induce CITICORP USA, INC., a Delaware
corporation, having its principal place of business at Citicorp Center, 666 Fifth Avenue, New York, New York 10103 (“Lender”), to lend to 57 AVIATION SERVICES, LLC, a Delaware limited liability company, whose principal place of business is
9 West 57th Street, 39th Floor, New York, New York 10019 (the “Borrower”), the principal sum of SIXTEEN MILLION SEVEN HUNDRED SIXTY-THREE THOUSAND SEVEN HUNDRED EIGHTEEN AND 53/100 DOLLARS ($16,763,718.53) (the “Loan”), evidenced
by the Promissory Note (the “Note”) and secured by an Amended and Restated First Priority Aircraft Mortgage and Security Agreement (the “Mortgage”), each as described in Exhibit A attached hereto and made a part hereof, and by
other documents executed in connection therewith (the “Other Security Documents”), 
 The undersigned, OZ MANAGEMENT LP, OZ
ADVISORS LP and OZ ADVISORS II LP, each a Delaware limited partnership with an office at 9 West 57th Street, 39th Floor, New York, New York 10019 (hereinafter referred to as “Guarantor”) hereby absolutely, joint and severally and
unconditionally guarantee to Lender the prompt and unconditional payment of the said principal sum and the interest thereon, as the same shall become due and payable under the Note, and any and all sums of money which, at any time, may become due
and payable under the provisions of the Note, the Mortgage or the Other Security Documents, including, without limitation all costs and expenses (including reasonable attorney’s fees) incurred by and the due and prompt performance of all of the
terms, agreements, covenants and conditions thereof (collectively, the “Debt”). 
 It is expressly understood and agreed that this
is a continuing guaranty and that the obligations of Guarantor hereunder are and shall be absolute under any and all circumstances, without regard to the validity, regularity or enforceability of the Note, the Mortgage, or the Other Security
Documents, a true copy of each of said documents Guarantor hereby acknowledges having received and reviewed. 
 Any indebtedness of Borrower
to Guarantor now or hereafter existing (including, but not limited to, any rights to subrogation Guarantor may have as a result of any payment by Guarantor under this Guaranty), together with any interest thereon, shall be, and such indebtedness is,
hereby deferred, postponed and subordinated to the prior payment in full of the Debt. Until payment in full of the Debt (and including interest accruing on the Note after the commencement of a proceeding by or against Borrower under the Bankruptcy
Reform Act of 1978, as amended, 11 U.S.C. Sections 101 et seq., and the regulations adopted and promulgated pursuant thereto (collectively, the “Bankruptcy Code”) which interest the parties agree shall remain a claim that is prior and
superior to any claim of Guarantor notwithstanding any contrary practice, custom or ruling in cases under the Bankruptcy Code generally), Guarantor agrees not to accept any payment or satisfaction of any kind of indebtedness (not to include any
equity distributions) of Borrower to Guarantor and hereby assigns such indebtedness to Lender, including the right to file proof of claim and to vote thereon in connection with any such proceeding under the Bankruptcy Code, including the right to
vote on any plan of reorganization. 

 Guarantor agrees that, with or without notice or demand, Guarantor will reimburse Lender, to the extent
that such reimbursement is not made by Borrower, for all expenses (including reasonable attorney’s fees) incurred by Lender in connection with the collection of the Debt or any portion thereof or with the enforcement of this Guaranty.

 All moneys available to Lender by Guarantor hereunder for application in payment or reduction of the Debt may be applied by Lender in such
manner and in such amounts and at such time or times and in such order and priority as Lender may see fit to the payment or reduction of such portion of the Debt as Lender may elect. 
 Guarantor hereby waives notice of the acceptance hereof, presentment, demand for payment, protest, notice of protest, or any and all notice of
non-payment, non-performance or non- observance, or other proof, or notice or demand. 
 Guarantor further agrees that the validity of this
Guaranty and the obligations of Guarantor hereunder shall in no way be terminated, affected or impaired (i) by reason of the assertion by Lender of any rights or remedies which it may have under or with respect to either the Note, the Mortgage,
or the Other Security Documents, against any person obligated thereunder, or (ii) by reason of any failure to file or record any of such instruments or to take or perfect any security intended to be provided thereby, or (iii) by reason of
the release or exchange of any property covered by the Mortgage or other collateral for the Loan, or (iv) by reason of Lender’s failure to exercise, or delay in exercising, any such right or remedy or any right or remedy Lender may have
hereunder or in respect to this Guaranty, or (v) by reason of the commencement of a case under the Bankruptcy Code by or against any person obligated under the Note, the Mortgage or the Other Security Documents, or the death of any Guarantor,
or (vi) by reason of any payment made on the Debt or any other indebtedness arising under the Note, the Mortgage or the Other Security Documents, whether made by Borrower or Guarantor or any other person, which is required to be refunded
pursuant to any bankruptcy or insolvency law; it being understood that no payment so refunded shall be considered as a payment of any portion of the Debt, nor shall it have the effect of reducing the liability of Guarantor hereunder. It is further
understood, that if Borrower shall have taken advantage of, or be subject to the protection of, any provision in the Bankruptcy Code, the effect of which is to prevent or delay Lender from taking any remedial action against Borrower, including the
exercise of any option Lender has to declare the Debt due and payable on the happening of any default or event by which under the terms of the Note, the Mortgage or the Other Security Documents, the Debt shall become due and payable, Lender may, as
against Guarantor, nevertheless, declare the Debt due and payable and enforce any or all of its rights and remedies against Guarantor provided for herein. 
 Guarantor further covenants that this Guaranty shall remain and continue in full force and effect as to any modification, extension or renewal of the Note, the Mortgage, or any of the Other Security Documents, that
Lender shall not be under a duty to protect, secure or insure any security or lien provided by the Mortgage or other such collateral, and that other indulgences or forbearance may be granted under any or all of such documents, all of which may be
made, done or suffered without notice to, or further consent of, Guarantor. 
  

 -2- 

 Guarantor agrees that so long as the Loan shall remain outstanding, OZ Management LP
(“Management”), OZ Advisors LP (“Advisors I”) and OZ Advisors II LP (“Advisors II”) shall maintain average Liquid Assets (hereinafter defined) in an aggregate amount that shall at all times (tested quarterly) be equal
to an amount greater than the then outstanding principal balance of the Note. The term “Liquid Assets” shall mean cash, unrestricted marketable securities and other liquid investments of the undersigned, including the undersigned’s
assets held at Lender or one of Lender’s affiliates, solely to the extent that each may be converted to cash within ninety (90) days, as determined by Lender in its reasonable discretion, without the consent of any person or entity.

 Guarantor further agrees that so long as the Loan shall remain outstanding, each of the Guarantors will, unless the Lender shall otherwise
consent in writing: (i) comply in all material respects with all applicable laws, rules, regulations and orders, such compliance to include, without limitation, paying before the same become delinquent all taxes, assessments and governmental
charges imposed upon the undersigned or the undersigned’s property, except to the extent contested in good faith and by appropriate proceedings; (ii) furnish or cause to be furnished to the Lender, as soon as available and in any event
within forty-five (45) days after the end of each calendar quarter and ninety (90) days from year end balance sheets and statements of income and retained earnings or other comparable financial statements of Och-Ziff Capital Management
Group, LLC as of the end of or for such quarter, which financial statements shall present fairly the financial condition and results of operations of each of the Och-Ziff Capital Management Group, LLC, as applicable, as of the end of or for the
period covered thereby and which interim statements shall be reviewed and certified as true and correct by Och-Ziff Capital Management Group, LLC and which annual year-end statements shall be audited by an independent certified public accountant
acceptable to Lender (it being understood that a “Big 4” accounting firm is acceptable) and prepared on a review quality basis, together with such other information respecting the condition or operations, financial or otherwise, of each of
the undersigned as the Lender may from time to time reasonably request in accordance with the requirements of the U.S. Securities and Exchange Commission (the “SEC”); provided, however, the Guarantors shall be relieved of the obligation to
deliver the foregoing periodic statements to the extent that (a) Lender is able to timely access the same from publicly available sources and (b) Lender notifies the Guarantors of its receipt of same prior to the expiration of the
foregoing period in which same are to be delivered to Lender (it being understood that Lender shall not declare an Event of Default with respect to Guarantors failure to deliver such periodic statements unless ten (10) Business Days have passed
from the date the Lender informed the Borrower in writing that the Lender was unable to access the applicable periodic statements from publicly available sources); and (iii) provide the Lender access to the books and financial records of each
of the undersigned from time to time to inspect and make copies of (at the undersigned’s expense) such books and records and to further provide the Lender with such other information respecting the condition, financial or otherwise, of the
Borrower, Management, Advisors I and Advisors II as the Lender may from time to time reasonably request (at the Guarantor’s expense). 
 Guarantor further agrees that so long as the Loan shall remain outstanding, (i) the Guarantors shall collectively maintain Net Economic Income on an accrual basis, which shall at all times (tested quarterly) exceed the amount equal to
three (3) times the annual principal payments and interest payments due on all direct or indirect debt of the Guarantors. For purposes of this provision, the term “Net Economic Income” shall mean Economic Income 

  

 -3- 

 
Revenues minus Economic Income Expenses. “Economic Income Revenues” shall mean management and incentive fees and all other revenues derived by the
Guarantors. “Economic Income Expenses” shall mean all compensation expenses and all other cash operating expenses; and (ii) the aggregate “Capital Under Management” of all Funds (as defined in the Note) for Guarantors must
exceed Twenty Billion Dollars ($20,000,000,000.00), tested quarterly. As used herein “Capital Under Management” shall mean the sum of all assets in the capital accounts of all of the partners or members, as applicable, of the Funds less
all liabilities. The constituency of the Funds may be altered in accordance with the terms of Section VIIIC of the Note. In no event shall Guarantors’ permit the aggregate Economic Income Revenues derived from management fees to decline by
forty percent (40%) of the Economic Income Revenues derived from management fees as of the year ended December 31, 2007 (which the parties agree were $476,907,000.00) tested annually. To the extent that Lender determines that such
financial tests and/or determinations are no longer available, Lender, in its sole discretion, shall select appropriate alternative financial tests and covenants. 
 As a further inducement to Lender to make the Loan and in consideration thereof, Guarantor further covenants and agrees (i) that in any action or proceeding brought by Lender against Guarantor on this Guaranty,
Guarantor shall and does hereby waive trial by jury, (ii) that the Supreme Court of the State of New York for the County of New York, or, in a case involving diversity of citizenship, the United States District Court for the Southern District
of New York, shall have jurisdiction of any such action or proceeding, (iii) that service of any summons and complaint or other process in any such action or proceeding may be made by registered or certified mail directed to Guarantor at
Guarantor’s addresses hereinabove set forth, Guarantor hereby waiving personal service thereof, and (iv) that within thirty (30) days after such mailing Guarantor so served shall appear or answer to any summons and complaint or other
process and should Guarantor so served fail to appear or answer within said thirty-day period, said Guarantor shall be deemed in default and judgment may be entered by Lender against the said party for the amount as demanded in any summons and
complaint or other process so served. 
 This is a guaranty of payment and not of collection and upon any default of the Borrower under the
Note, the Mortgage or the Other Security Documents, Lender may, at its option, proceed directly and at once, without notice, against Guarantor to collect and recover the full amount of the liability hereunder or any portion thereof, without
proceeding against Borrower or any other person, or foreclosing upon, selling, or otherwise disposing of or collecting or applying against any of the pledged property or other collateral for the Loan. Guarantor hereby waives the pleading of any
statute of limitations as a defense to the obligation hereunder. 
 Each reference herein to Lender shall be deemed to include its successors
and assigns, to whose favor the provisions of this Guaranty shall also inure. Each reference herein to Guarantor shall be deemed to include the heirs, executors, administrators, legal representatives, successors and assigns of Guarantor, all of whom
shall be bound by the provisions of this Guaranty. 
 Guarantor (and its representative, executing below, if any) has full power, authority
and legal right to execute this Guaranty and to perform all its obligations under this Guaranty. 
  

 -4- 

 All understandings, representations and agreements heretofore had with respect to this Guaranty are
merged into this Guaranty which alone fully and completely expresses the agreement of Guarantor and Lender. 
 This Guaranty may not be
modified, amended, waived, extended, changed, discharged or terminated orally or by any act or failure to act on the part of Lender, Borrower or Guarantor, but only by an agreement in writing signed by the party against whom enforcement of any
modification, amendment, waiver, extension, change, discharge or termination is sought. 
 This Guaranty shall be governed, construed and
interpreted as to validity, enforcement and in all other respects, in accordance with the laws of the State of New York. 
 The Guarantor
agrees from time to time within twenty (20) days of request by Lender to do and perform such other and further acts and execute and deliver any and all such instruments as may be required by applicable law or reasonably requested by the Lender
to establish, maintain or protect the rights and remedies of the Lender or to carry out and effect the intent and purpose of this Guaranty. 
 All notices hereunder shall be in writing and sent by certified or registered mail, return receipt requested, or by overnight delivery service, with all charges prepaid. Notices to the Lender shall be sent to its address set forth in
paragraph 1 above until the Lender specifies another address in a notice delivered to the Guarantor in accordance with this paragraph. Notices to the Guarantor shall be sent to the address set forth in paragraph 2 above until the Guarantor specifies
another address in a notice delivered to the Lender in accordance with this paragraph. Notices will be deemed received on the date set forth in a confirmation or receipt of delivery or on the date of rejection of delivery, as the case may be.

 [NO FURTHER TEXT ON THIS PAGE/ 
 SIGNATURE PAGE FOLLOWS] 
  

 -5- 

 IN WITNESS WHEREOF, Guarantor has duly executed this Guaranty as of the date first above set forth.

  

					
	OZ MANAGEMENT LP,
	a Delaware limited partnership
		
	By:	 	Och-Ziff Holding Corporation,
		 	a Delaware corporation,
		 	its general partner
			
		 	By:	 	/s/ Joel Frank
		 		 	Name: Joel Frank
		 		 	 Title: Chief Financial Officer

 [SIGNATURE PAGE CONTINUES ON NEXT PAGE] 
 GUARANTY OF PAYMENT 

					
	OZ ADVISORS LP,
	a Delaware limited partnership
		
	By:	 	Och-Ziff Holding Corporation,
		 	a Delaware corporation,
		 	its general partner
			
		 	By:	 	/s/ Joel Frank
		 		 	Name: Joel Frank
		 		 	Title: Chief Financial Officer

 [SIGNATURE PAGE CONTINUES ON NEXT PAGE] 
 GUARANTY OF PAYMENT 

					
	OZ ADVISORS II LP,
	a Delaware limited partnership
		
	By:	 	Och-Ziff Holding LLC,
		 	a Delaware limited liability company,
		 	its general partner
			
		 	By:	 	/s/ Joel Frank
		 		 	Name: Joel Frank
		 		 	Title: Chief Financial Officer

 GUARANTY OF PAYMENT 

 EXHIBIT A 
 (a) Promissory Note in the principal sum of $16,763,718.53 made by 57 AVIATION SERVICES, LLC, as Payee and dated May 30, 2008 (the “Note”). 
 (b) Amended and Restated First Priority Aircraft Mortgage and Security Agreement securing the principal sum of $16,763,718.53 given by 57 AVIATION
SERVICES, LLC, as Grantor to Citicorp USA, Inc. as Mortgagee, dated May 30, 2008 (the “Mortgage”).Third Amendment to License Agreement - Elan Pharma International Ltd.

 Exhibit 10.33 
 EXECUTION VERSION 
 THIRD AMENDMENT TO LICENSE AGREEMENT 
 This THIRD AMENDMENT (“Third Amendment”) is made and entered into as of the date upon which this Third Amendment is fully executed by
both Parties (the “Third Amendment Effective Date”). 
 BETWEEN: 
  

	(1)	Elan Pharma International Limited, a company incorporated under the laws of Ireland, and having its registered office at Monksland, Athlone, County Westmeath, Ireland
(“EPIL”); and 

  

	(2)	MAP Pharmaceuticals, Inc., a company incorporated under the laws of Delaware, having its principal place of business at 2400 Bayshore Parkway, Suite 200, Mountain View, CA
94043, USA (“MAP”). 

 RECITALS: 
 WHEREAS, EPIL and MAP entered into a License Agreement on February 3, 2005, as amended on September 15, 2006 and June 18, 2007 (the “License Agreement”), whereby EPIL granted to MAP,
among other rights, an exclusive, sublicensable license to EPIL Intellectual Property for the sole purpose of, and only to the extent necessary for, using, marketing, distributing, selling, having sold, offering for sale, importing and exporting the
Product in the Field in the Territory; 
 WHEREAS, MAP intends to grant a sublicense under the License Agreement to AstraZeneca AB
with respect to the Product (the “Sublicense”); and 
 WHEREAS, EPIL and MAP now desire to amend the License Agreement as
set forth below. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
EPIL and MAP hereby agree, effective as of the Third Amendment Effective Date, as follows: 
 1. Clause 2.1.1 of the License Agreement shall be deleted in
its entirety and replaced with the following: 
 “Subject to the terms of this Agreement, EPIL hereby grants to MAP a
non-exclusive sublicensable license in the Field in the Territory to the EPIL Intellectual Property for the sole purpose of, and only to the extent necessary for, making and having made the Product Intermediate in [***] for use in the Field in the
Territory, or making and having made the Product Intermediate in any other country in the Territory as agreed by EPIL at its sole discretion.” 
  
 [*] = Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 
  

 1 

 2. Clause 2.1.2 of the License Agreement shall be deleted in its entirety and replaced with the following: 
 “EPIL acknowledges that MAP or its Sublicensee may contract with a Third Party to further process Product Intermediate into Product
for use in a Device. EPIL agrees to provide such Third Party with a royalty-free, non-exclusive license to any EPIL Intellectual Property to the limited extent necessary for the Third Party to process Product Intermediate into packaged form for use
in a Device.” 
 3. Clause 2.2.0 of the License Agreement shall be deleted in its entirety and replaced with the following: 
 “MAP shall have the right to grant sublicenses of the rights licensed by EPIL to MAP under Clauses 2.1.0 and 2.1.2 herein. MAP shall
have the right to grant sublicenses of the rights licensed by EPIL to MAP under Clause 2.1.1 herein [***]. MAP shall be entitled to grant sublicenses under Clauses 2.1.0 and 2.1.2 through multiple tiers of sublicensees for the purpose of MAP’s
Sublicensees, under Clauses 2.1.0 and 2.1.2, exercising their rights and performing their obligations through their (a) Affiliates or (b) further sublicensees[***] and with a [***] on any [***]. MAP shall notify EPIL of the identity of
each Sublicensee, including any further permitted sublicensee (and the territory sublicensed to it) promptly after such arrangement is entered into. All such additional permitted sublicensees shall be deemed to be included within the defined term
“Sublicensee” for purposes of this Agreement and the Services Agreement. Additionally, MAP shall notify EPIL promptly after MAP receives notice from its Sublicensees of any Regulatory Approvals or the filing of any New Drug Application or
equivalent thereof in a country other than the United States for Product. 
 The Parties acknowledge and agree that EPIL has
an interest in maintaining the confidentiality of certain information contained in [***] Notwithstanding anything in Clause 4.7 to the contrary, EPIL shall provide to MAP or its Sublicensee access to [***] and information with respect thereto as
reasonably necessary to obtain or maintain Regulatory Approvals with respect to Product in [***]; provided that MAP or its Sublicensee, as applicable, shall (i) use diligent efforts to (A) maintain the confidentiality of such information
(to the extent permitted under applicable laws) and (B) seek to eliminate or minimize the disclosure of information (to the extent permitted under applicable law) in respect of which confidentiality cannot legally be so maintained, and
(ii) provide EPIL a reasonable opportunity to comment, and consider in good faith any such comments, with respect to the disclosure of such information and the strategy for protecting (to the extent permitted under applicable law) the
confidentiality of such information in connection with regulatory activities in such country.” 
  
 [*] = Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 2 

 4. Clause 2.2.1 of the License Agreement shall be deleted in its entirety and replaced with the following: 
 “Notwithstanding the specific references to Sublicensees (and the Sublicensee Counter Party) in certain terms of this Agreement, any
sublicense granted hereunder shall be on the same terms mutatis mutandis as the terms of this Agreement insofar as such terms are applicable.” 
 5. Clause 3.4.3 of the License Agreement shall be deleted in its entirety and replaced with the following: 
 “If [***] does not settle with the infringer or bring suit or other proceeding against the infringer within [***] after receipt of written notice from [***] or such other time frame as mutually agreed in writing by the Parties, [***]
may in its discretion, bring suit or other proceeding at its expense against the infringer. [***] shall be kept advised at all times of such suit or proceedings brought by [***]. 
 Notwithstanding the foregoing, in the event [***] shall [***] so notify [***] and the Parties shall discuss the appropriate response in
good faith. [***] shall make a determination whether it will enforce the applicable EPIL Intellectual Property within [***] thereafter and, if [***] declines to bring such action within such time period, [***] may at its discretion bring a lawsuit
or action or initiate another proceeding at its expense against the infringer. In any such action to enforce the applicable EPIL Intellectual Property, MAP and EPIL agree to [***] of such action.” 
 6. The first two sentences of Clause 3.8 of the License Agreement are hereby amended and restated as follows: 
 “If MAP or its Sublicensee is required by an act of a court of competent jurisdiction in any country in the Territory to make payments to one or more
independent Third Parties to obtain license or similar rights in order to exercise the rights granted to it by EPIL under Clause 2.1 of this Agreement (the “Third Party Payments”), then either (i) MAP or its Sublicensee shall
have the right to [***], or (ii) [***]. Notwithstanding the foregoing, subject to [***], if [***] elects to settle such infringement claim with such Third Party prior to a final decision of a court of competent jurisdiction, [***]”

 7. A new Clause 3.10 of the License Agreement shall be added as follows: 
 “EPIL shall (a) [***] MAP and its Sublicensees as to the strategy and prosecution of the patents and/or patent applications [***] (namely the identified [***] patents and patent applications and any
counterparts thereof [***], and all divisional, continuations, continuations-in-part, and all patents issuing on any of the foregoing, and any counterparts thereof [***], together with all registrations, reissues, re-examinations, supplemental
protection certificates or extensions of term thereof) [***], (b) [***] MAP and its Sublicensees with a [***], and (c) [***] MAP or its Sublicensees [***] to patent authorities in respect of foreign counterparts of the [***] patents and
patent applications [***] other than [***]. For the purposes of this Clause 3.10: (1) [***] EPIL will [***] from MAP or its 
  
 [*] = Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 
  

 3 

 
Sublicensee, [***]. For the avoidance of doubt, [***]. Further, EPIL shall [v] MAP and its Sublicensees the [***] with respect to any defence and/or
enforcement of the EPIL Intellectual Property (including the [***]) as it relates to the Product or Product Intermediate; provided that the foregoing sentence shall not modify the decision making with respect to the defence or enforcement of such
EPIL Intellectual Property as provided in Clause 3.4. In the event that [***] in circumstances [***] shall, as soon as reasonably practicable thereafter, notify [***] of the action taken. Other than as provided in Clause 3.4 and the foregoing
sentence [***] in respect of defence and / or enforcement of EPIL Intellectual Property. Upon request from [***] listed patents and applications, and add new divisional, continuation or continuation-in-part applications, provided that such revision
shall occur no more than biannually.” 
 8. Clause 4.1 of the License Agreement shall be deleted in its entirety and replaced with the following:

 “MAP or its Sublicensee, as applicable, shall (a) use Commercially Reasonable Efforts to develop and obtain Regulatory Approval
of Product [***], (b) [***] and (c) in the event MAP or its Sublicensee, as applicable, [***], use Commercially Reasonable Efforts to develop and obtain Regulatory Approval of Product [***]. For clarity, MAP or its Sublicensee, as
applicable, shall have [***]. After each Regulatory Approval thereof, MAP and its Sublicensees shall use Commercially Reasonable Efforts to commercialise Product [***] in the country where Regulatory Approval was obtained; provided that the
foregoing shall not require MAP or its Sublicensees to [***]. MAP or its Sublicensees, as applicable, shall ensure that the Product is treated [***]. MAP covenants that it and its Sublicensee shall not [***] a [***]. Without expanding the
remainder of this Clause 4.1, MAP acknowledges that the [***] with respect to the development and commercialisation of a Product [***]. MAP or its Sublicensee will evaluate [***]. If MAP or its Sublicensee determines that [***], then MAP and its
Sublicensee shall [***] in accordance with the foregoing provisions of this Clause 4.1. Further, MAP shall notify EPIL of any [***] and shall consult with, give EPIL the [***], and [***] any [***] with respect to any [***].” 
 9. A new Clause 4.9 of the License Agreement shall be added as follows: 
 “Except as otherwise provided in the Services Agreement or in any other manufacturing agreement with respect to Product Intermediate between EDDI or any of its Affiliates and MAP or a Sublicensee (all such
manufacturing agreements shall be deemed to be included within the defined term “Manufacturing Agreement” for purposes of this Agreement and the Services Agreement), MAP and its Sublicensee shall obtain [***].” 
 10. A new Clause 4.10 of the License Agreement shall be added as follows: 
 “Establishment of Committee. [***] shall establish a committee to provide for sharing of information, and, where applicable, the [***] activities under the Services Agreement or any Manufacturing
Agreement with respect to: (a) [***]; (b) the manufacture and supply of Product Intermediate; and (c) the [***], including [***] Upon EPIL’s reasonable request, MAP [***] shall provide to EPIL [***]” 
  
 [*] = Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 4 

 11. The last sentence in Clause 7.3 of the License Agreement shall be deleted in its entirety. 
 12. Clause 10.1.2 of the License Agreement shall be deleted in its entirety and replaced with the following: 
 “Any Confidential Information disclosed by the disclosing Party shall be used by the receiving Party exclusively for the purposes of fulfilling the
receiving Party’s obligations and exercising rights under this Agreement or a Related Agreement and for no other purpose.” 
 13. Clause 10.1.3 of
the License Agreement shall be deleted in its entirety and replaced with the following: 
 “Except as otherwise specifically provided
herein, and subject to Clauses 10.2 and 10.3, each Party shall disclose Confidential Information of the other Party only to those employees (including employees of its Affiliates), representatives, permitted sublicensees and agents requiring
knowledge thereof in connection with fulfilling the Party’s obligations and exercising rights under this Agreement or a Related Agreement, and not to any other Third Party. Each Party further agrees to inform all such employees,
representatives, permitted sublicensees and agents of the terms and provisions of this Agreement relating to Confidential Information and their duties hereunder and to obtain or have obtained their agreement to keep such Confidential Information in
confidence under terms and conditions no less restrictive than those contained herein.” 
 14. Clause 1.1 of the License Agreement shall be amended by
the addition of the following definition: 
 “ “Sublicense Counter Party” shall mean AstraZeneca AB.” 
 15. Schedule 1 of the License Agreement shall be deleted in its entirety and replaced with the schedule set forth in Exhibit A. 
 16. All other terms and conditions of the License Agreement remain unchanged and continue to be in full force and effect. 
 17. Capitalized terms not defined in this Third Amendment shall have the meaning as set forth in the License Agreement. 
 18. EPIL [***] the sublicense by MAP to the Sublicense Counter Party of the rights granted to it under Clause 2.1.1 of the License Agreement (including those amendments
to the License Agreement agreed to pursuant to this Third Amendment) upon the terms relevant to EPIL that have been [***] (a) to [***] or (b) that [***]. EPIL and MAP hereby acknowledge that such terms are intended by MAP to represent
those terms of the said sublicense which will be relevant to EPIL and do not constitute the full terms of such sublicense. Nothing in this Section 17 shall 
  

[*] = Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 
  

 5 

 
be deemed a waiver of any of EPIL’s rights set forth in Clauses 2.2.1 through 2.2.6 of the License Agreement (including any amendment to such Clauses
agreed to pursuant to this Third Amendment), with respect to such sublicense. For clarity, such consent shall not be taken to extend the rights granted to MAP under the License Agreement, except as expressly set out in this Third Amendment.

 19. This Third Amendment shall be null and void and have no further force or effect if either (i) MAP does not execute the Sublicense prior to [***]
or (ii) the Sublicense is terminated before it becomes effective in accordance with its terms. For the avoidance of doubt, in the event of circumstance (ii) in the previous sentence, EPIL and MAP shall revert to their status with respect
to the License Agreement as if this Third Amendment had not been executed. 
 20. This Third Amendment shall be governed by and construed solely in
accordance with the laws of the State of New York, without regard to its conflict of laws principles that would require the application of any other law. 
 21. This Third Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute this Third Amendment. 
  
 [*] = Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 6 

 IN WITNESS WHEREOF, EPIL and MAP have caused this Third Amendment to the License Agreement to be
executed by their duly authorized representatives as of the last date set forth below. 
  

			
	ELAN PHARMA INTERNATIONAL LIMITED
		
	By:	 	/s/ Shane Cooke
	Title:	 	Director
		
	Date:	 	December 18, 2008
	
	MAP PHARMACEUTICALS, INC.
		
	By:	 	/s/ Timothy S. Nelson
	Title:	 	President & CEO
		
	Date:	 	December 18, 2008

  
 [*] = Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit A 
 [***] 
  
 [*] = Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]